The firm said it will stop enrolling a late-stage trial in blood cancers to prioritize a preclinical in vivo T-cell receptor program in solid tumors.
Three patients reportedly died after side effects from Novartis' rap-cel, and BMS has observed some inflammatory events in patients after zola-cel.
Amsterdam-based UniQure developed AMT-130 to slow progression of Huntington's disease, a fatal, progressive neurodegenerative disease caused by mutations in the huntingtin gene. The gene therapy is ...
After discussions with the FDA, the firm believes it has a regulatory path to bringing Illuccix and Gozellix into the pre-biopsy setting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results